Brief: Algernon Files FDA Pre-IND Meeting Request For Lung Cancer Treatment Study
22/09/2021 13:48
Sept 22 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS FILES U.S. FDA PRE-IND MEETING
REQUEST
FOR IFENPRODIL SMALL CELL LUNG CANCER STUDY
Source text for Eikon: ID:nGNXYqQX8
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement